Valuation: Axsome Therapeutics, Inc.

Market Cap 12.27B 10.78B 10.04B 9.22B 17.31B 1,176B 17.54B 119B 46.6B 581B 46.05B 45.05B 2,008B P/E 2026 *
-116x
P/E 2027 * 42.9x
Enterprise Value 12.16B 10.69B 9.95B 9.14B 17.15B 1,166B 17.38B 118B 46.18B 576B 45.63B 44.65B 1,990B EV / Sales 2026 *
12.4x
EV / Sales 2027 * 7.44x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week+7.55%
Current month-2.61%
1 month-1.37%
3 months+27.20%
6 months+26.78%
Current year+30.51%
1 week 233.73
Extreme 233.73
245.5
1 month 221.21
Extreme 221.21
252.6
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/11/26 Sell

Director

-286 0.0006%
6/10/26 Sell

Director

-643 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%+7.55%+136.41%+208.01% 12.4B
+1.70%-0.74%+18.48%-10.41% 66.74B
-0.08%+3.28%+37.97%+203.98% 53.32B
+1.78%+54.50%+54.50%+54.50% 48.12B
+0.67%-3.39%-56.67%-56.04% 38.25B
-1.01%+0.10%+52.17%-23.84% 29.85B
+1.02%+2.78%+69.33%+89.65% 23.51B
+2.89%-6.49%+62.90%-53.06% 21.45B
+0.12%+4.16%+81.68%+161.81% 16.47B
+1.44%+0.22%+65.12%+126.78% 16.38B
Average +0.75%+1.03%+52.19%+70.14% 32.65B
Weighted average by Cap. +0.89%+1.23%+37.84%+55.86%

Financials

2026 *2027 *
Net sales 979M 861M 801M 736M 1.38B 93.88B 1.4B 9.52B 3.72B 46.36B 3.67B 3.6B 160B 1.6B 1.4B 1.31B 1.2B 2.25B 153B 2.28B 15.53B 6.06B 75.59B 5.99B 5.86B 261B
Net income -107M -94.32M -87.8M -80.64M -151M -10.29B -153M -1.04B -408M -5.08B -403M -394M -17.56B 309M 272M 253M 232M 436M 29.64B 442M 3.01B 1.17B 14.64B 1.16B 1.14B 50.59B
Net Debt -111M -97.31M -90.59M -83.19M -156M -10.62B -158M -1.08B -421M -5.24B -416M -407M -18.12B -394M -346M -322M -296M -556M -37.76B -563M -3.83B -1.5B -18.65B -1.48B -1.45B -64.45B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-27 US$238.37 -1.09% 773,051
26-07-24 US$241.00 -0.22% 461,989
26-07-23 US$241.53 +0.80% 500,364
26-07-22 US$239.62 +1.13% 648,276
26-07-21 US$236.95 +6.91% 993,638
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
238.37USD
Average target price
282.51USD
Spread / Average Target
+18.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock